Dear Colleagues,
Could a change in shape for an immediate release tablet (with supportive data and update of the PI) without a quantitative/qualitative change in formulation be submitted to a NDA as a CBE or CBE-30?
Thank you for your advice.
Best regards,
David Lucking
------------------------------
David Lucking
FL
United States
------------------------------